Keywords: gw, abacavir, expanded-access, glaxo, wellcome, new, reverse
GW's Abacavir In Expanded-Access
Article | 19 March 1998
Glaxo Wellcome's new reverse transcriptase inhibitor Ziagen (abacavir)is to be made available through an expanded-access program for people with ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
